
Regeneron and Sanofi’s Dupilumab is the first biologic to demonstrate a clinically meaningful and statistically significant reduction in exacerbations compared with the placebo.

Regeneron and Sanofi’s Dupilumab is the first biologic to demonstrate a clinically meaningful and statistically significant reduction in exacerbations compared with the placebo.

Studies show that patients who are introduced to patient support programs through digital platforms are more likely to use support services.

Products include multivitamin gummies and a superfood supplement.

Eflapegrastim-xnst subcutaneous injection (Rolvedon) reduces infections related to febrile neutropenia in adults with nonmyeloid malignant tumors who are being treated with certain anticancer drugs.

FDA action allows for OTC naloxone (Narcan) to be sold directly to consumers in pharmacies, convenience stores, grocery stores, gas stations, and online.

Increased risk for severe disease in individuals with SUD could be from co-occurring medical conditions, investigators from Boston Medical Center say.

Muneeb Shah, DO, dermatologist and partner at PC Dermatology PLLC, and Reid Maclellan, MD, founder of Cortina Health Inc also discuss the role technology and social media play in health care education.

Data indicated that waist-to-height ratio is a better indicator of outcomes in patients with HF than body mass index.

Removing the word ‘risk’ from discussions of HIV PrEP and focusing more on environment and empowerment concerns are beneficial in this patient population.

There has not yet been established a consensus on the set of factors to use for assessing social determinants of health in practice.

Any living person with HIV should be screened for hepatitis B and C upon diagnosis, with annual screenings recommended for those with additional risk factors.

Products include a new NSAID and an oral solution for depression.

Given the promising results, the company is advancing Rinvoq to a phase 3 clinical trial for the autoimmune disorder.

Keeping a finger on the technician community's pulse is imperative to support pharmacies' needs.

Triana Moore, CPhT, CSPT, a pharmacy regulatory specialist at Novant Health, discusses compliance and regulation as an alternative career path for pharmacy technicians.

The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.

It is important for pharmacists to understand implications related to drug clearance to maximize therapeutics in patients with kidney disease.

Pharmacists on duty decline to dispense the medication to manage COVID-19, raising question about self-determination.

More and more data, both from real world analyses and clinical trials, are shedding light on the effective uses of cannabis, as well as the contraindications for its use in patients.

Even the terms themselves, “sex” and “gender,” are often misused and misunderstood by US society and medical professionals alike.

Imminent March, April expiration dates indicate changes are on the horizon for pharmacy services.

Therapy from Karuna Therapeutics demonstrates an 8.4-point reduction in Positive and Negative Syndrome Scale total score compared with the placebo at week 5.

Muneeb Shah, DO, dermatologist and partner at PC Dermatology PLLC, and Reid Maclellan, MD, founder of Cortina Health Inc, tackle misinformation and myths surrounding sun screen, skin cancer, and acne.

Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, discusses some of the ways that social determinants of health can impact patient health outcomes.

Although attention-deficit/hyperactivity disorder (ADHD) is not as common in adults, it can still be present and bothersome, however, adults with ADHD may have learned to hide it a bit better than children.

Prior to the pandemic, the seasonality of respiratory syncytial virus followed a pattern; now, this pattern of disease spread has changed significantly.

Specifically, non-opioids are often preferred for the management of subacute and chronic pain because of their safety profiles.

Pharmacy Times is covering the American Pharmacists Association (APhA) Annual Meeting & Exposition in Phoenix, Arizona from March 24 to 27, 2023.

Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, discusses current outlook on the occurrence of outbreaks of vaccine-preventable diseases in the country.

Specifically, 3 new drugs for sickle cell disease are providing options for patients who are not responding to hydroxyurea.